| |  Online-Ressource |
|---|
| Verfasst von: | Eickelschulte, Samaneh [VerfasserIn]  |
|---|
| | Riediger, Anja Lisa [VerfasserIn] |
|---|
| | Angeles, Arlou Kristina J. [VerfasserIn] |
|---|
| | Janke, Florian [VerfasserIn] |
|---|
| | Duensing, Stefan [VerfasserIn] |
|---|
| | Sültmann, Holger [VerfasserIn] |
|---|
| | Görtz, Magdalena [VerfasserIn] |
|---|
| Titel: | Biomarkers for the detection and risk stratification of aggressive prostate cancer |
|---|
| Verf.angabe: | Samaneh Eickelschulte, Anja Lisa Riediger, Arlou Kristina Angeles, Florian Janke, Stefan Duensing, Holger Sültmann and Magdalena Görtz |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 11 December 2022 |
|---|
| Umfang: | 24 S. |
|---|
| Fussnoten: | Gesehen am 21.02.2023 |
|---|
| Titel Quelle: | Enthalten in: Cancers |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 14(2022), 24, Artikel-ID 6094, Seite 1-24 |
|---|
| ISSN Quelle: | 2072-6694 |
|---|
| Abstract: | Current strategies for the clinical management of prostate cancer are inadequate for a precise risk stratification between indolent and aggressive tumors. Recently developed tissue-based molecular biomarkers have refined the risk assessment of the disease. The characterization of tissue biopsy components and subsequent identification of relevant tissue-based molecular alterations have the potential to improve the clinical decision making and patient outcomes. However, tissue biopsies are invasive and spatially restricted due to tumor heterogeneity. Therefore, there is an urgent need for complementary diagnostic and prognostic options. Liquid biopsy approaches are minimally invasive with potential utility for the early detection, risk stratification, and monitoring of tumors. In this review, we focus on tissue and liquid biopsy biomarkers for early diagnosis and risk stratification of prostate cancer, including modifications on the genomic, epigenomic, transcriptomic, and proteomic levels. High-risk molecular alterations combined with orthogonal clinical parameters can improve the identification of aggressive tumors and increase patient survival. |
|---|
| DOI: | doi:10.3390/cancers14246094 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/cancers14246094 |
|---|
| | Volltext: https://www.mdpi.com/2072-6694/14/24/6094 |
|---|
| | DOI: https://doi.org/10.3390/cancers14246094 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | early detection |
|---|
| | liquid-based biomarkers |
|---|
| | prostate cancer |
|---|
| | risk stratification |
|---|
| | tissue-based biomarkers |
|---|
| K10plus-PPN: | 1837179263 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Biomarkers for the detection and risk stratification of aggressive prostate cancer / Eickelschulte, Samaneh [VerfasserIn]; 11 December 2022 (Online-Ressource)
